The study was considered negative because it Clofarabine Clolar is not their prime Endpoint of objective response rate according to Ren RECIST. These data are in contrast to a phase II trial of another mTOR inhibitor everolimus, used in combination with 5 or 10 mg 30 mg of octreotide. The study showed that 22% of patients had a partial response and 70% had stable disease. The promising phase II everolimus led to two randomized Phase III. RADIANT 2 was a randomized trial evaluating everolimus 10 mg of t Resembled versus placebo in 429 patients with malignant carcinoid Progressive functionability compatibility available. The median progression-free survival was 16.4 months to 11.3 months compared to arm in arm everolimus plus best supportive care. However, the PFS is not their prime Ren endpoint PFS conferred on central radiology and the difference was not statistically different basis are fulfilled. RADIANT 3 was, but clearly. This study was a Phase III study of everolimus 10 mg / day plus best supportive care alone in 410 patients with progressive panNETs.
This study showed a significant improvement of 2.4 times the median progression-free survival time. Side effects associated with everolimus consisted of stomatitis, rash, diarrhea, fatigue, infection and Pr Prevalence of upper respiratory tract. As mentioned sunitinib trial Above, it is not clear that the duration of each of these toxicity Th is important that patients requiring chronic treatment. The h Ufigsten grade 3 or 4 drug-related adverse events were stomatitis, An Chemistry and hyperglycemia Chemistry. The above data show clear clinical antitumor activity t of sunitinib, and everolimus, however, it is important to Recogn However, that patients enrolled in these studies had progressive disease. Patients with advanced NET have h Frequently indolent disease and may expectantly at times for months or even years to be followed without treatment. A sorgf insurance valid for evaluation of each patient with a anf Nglichen interval of observation and analysis of k You can find out who needs more treatment, tt is likely to do against the well without treatment over a liter Extended period is. It is important to remember that all therapies and interventions involve risks and side effects. The adverse event profile of sunitinib, and everolimus are predictable, but can The quality of life T adversely Mighty and should be considered.
As mentioned above HNT are carcinoid tumors And the other networks found Rich tumors, the h Expressed frequently and VEGF. Bevacizumab has been randomized in a phase II study in 44 patients with advanced or metastatic NET to receive either pegylated IFN 2b or bevacizumab tested. There was a partial response rate of 18% in the bevacizumab group, compared to 0% in the IFN 2b. At the age of 18 weeks were 96% of patients treated with bevacizumab progression-free compared to 68% of patients treated with IFN 2b. Hypertension grade 3 or 4 at 53%, markedly Higher than the 21%, 11 in the c Pivot-lon, lung and breast cancer studies has been established to report, but easy to control It with antihypertensive drugs. It should be noted that 40% of patients in the bevacizumab has no documentation of progression of the disease at the start of the study. A Phase III trial of bevacizumaboctreotide against IFNoctreotide is currently underway. Radiolabeled somatostatin analogue therapy.